Drug-Induced Organ Injury Biomarkers

About Firalis

Firalis is a privately-held, revenue-generating biotechnology company operating as a specialized Contract Research Organization (CRO) and diagnostic developer. Leveraging its strategic location in Europe's pharmaceutical hub and a unique network of clinical experts, the company focuses on translational biomarker science across inflammatory disorders, cardiovascular diseases, neurodegenerative conditions, and drug safety. Its business model combines fee-for-service biomarker research with internal diagnostic product development, supported by significant EU research grants and consortia leadership. The company's goal is to improve therapeutic decisions and reduce healthcare costs through validated biomarker-based tools.

Therapeutic Areas